Published online April 9, 2007
PEDIATRICS Vol. 119 No. 5 May 2007, pp. e1116-e1120 (doi:10.1542/peds.2006-2802)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kline, M. W.
Right arrow Articles by Schwarzwald, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kline, M. W.
Right arrow Articles by Schwarzwald, H. L.
Related Collections
Right arrow Infectious Disease & Immunity

ARTICLE

Long-term Follow-up of 414 HIV-Infected Romanian Children and Adolescents Receiving Lopinavir/Ritonavir-Containing Highly Active Antiretroviral Therapy

Mark W. Kline, MDa,b, Sorin Rugina, MDc, Margareta Ilie, MDc, Rodica F. Matusa, MDc, Ana-Maria Schweitzer, MAa,b, Nancy R. Calles, BSN, RNa,b and Heidi L. Schwarzwald, MDa,b

a Baylor College of Medicine International Pediatric AIDS Initiative, Texas Children's Hospital, Houston, Texas
b Baylor Black Sea Foundation, Constanta, Romania
c Infectious Diseases Hospital, Constanta, Romania

BACKGROUND. There are no published reports of the long-term safety and effectiveness of highly active antiretroviral therapy for children and adolescents living in resource-limited settings or of large cohorts of HIV-infected children and adolescents treated long-term (>48 weeks) with lopinavir/ritonavir-containing highly active antiretroviral therapy.

OBJECTIVES. The purpose of this work was to evaluate the long-term outcomes of treatment of HIV-infected children and adolescents with lopinavir/ritonavir-containing highly active antiretroviral therapy in a resource-limited setting.

METHODS. We studied an inception cohort of 414 HIV-infected children receiving lopinavir/ritonavir-containing highly active antiretroviral therapy between November 2001 and August 2006 at the Romanian-American Children's Center in Constanta, Romania. The center provides comprehensive primary and HIV specialty care and treatment to all known HIV-infected children and adolescents living in Constanta. We measured safety and effectiveness by the percentage of children remaining on treatment, rates of mortality, and changes in plasma HIV RNA concentrations and CD4+ lymphocyte counts.

RESULTS. The study population consisted predominantly of antiretroviral drug–experienced older children and adolescents with advanced HIV disease. Treatment was well tolerated, with 337 children (81%) remaining on therapy after a median duration of >4 years. Thirty-seven deaths occurred; the death rate compared favorably to prospectively collected historical data. The most recent on-treatment plasma HIV RNA concentration was <400 copies per milliliter in 192 of 265 children tested. The mean baseline CD4+ lymphocyte count was 292 cells per microliter (n = 299); the mean change from baseline was +266 (n = 284), +317 (n = 260), +343 (n = 176), and +270 cells per microliter (n = 121) after 1, 2, 3, and 4 years of treatment, respectively.

CONCLUSIONS. Highly active antiretroviral therapy can be administered safely and effectively to children and adolescents in resource-limited settings. Lopinavir/ritonavir-containing highly active antiretroviral therapy is a safe, effective, and durable treatment option for antiretroviral drug–experienced older children and adolescents with advanced HIV disease.

Key Words: HIV infection • child • adolescent • lopinavir

Abbreviations: HAART—highly active antiretroviral therapy • BIPAI—Baylor College of Medicine International Pediatric AIDS Initiative

Accepted Nov 13, 2006.




This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
B. Larru, S. Resino, J. M. Bellon, M. I. de Jose, C. Fortuny, M. L. Navarro, M. D. Gurbindo, J. T. Ramos, P. Soler Palacin, J. A. Leon, et al.
Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children
J. Antimicrob. Chemother., January 1, 2008; 61(1): 183 - 190.
[Abstract] [Full Text] [PDF]